-
NHHR Shows Great Potential in Predicting MASLD in Obese and Type 2 Diabetes Populations
Non-high-density lipoprotein cholesterol (Non-HDL-C) is calculated by subtracting high-density lipoprotein cholesterol (HDL-C) from total cholesterol (TC). The ratio of Non-HDL-C to HDL-C (NHHR) is an emerging composite lipid marker. Previous…
-
Introducing the Val d’Isère – Vilgrain Radiology Congress 2025!
Exciting news for the radiology community! Professor Valérie Vilgrain is organizing the inaugural Val d’Isère – Vilgrain Radiology Congress, set to take place from March 24-28, 2025, in the stunning…
-
Dr. Xuefeng Luo: Precision Reduction of Portal Pressure to Balance Ascites Control and Hepatic Encephalopathy Risk After TIPS
Background: The Clinical Dilemma of TIPS – A Double-Edged Sword in Cirrhosis Treatment Cirrhosis is a major global health burden, causing approximately 170,000 deaths annually in Europe alone (Pimpin L,…
-
New Study on ATM, CHEK2, and PALB2 Variants: No Significant Impact on Cancer Mortality
A recent study published in the Journal of Clinical Oncology provides important insights into the prognostic role of pathogenic variants (PVs) in ATM, CHEK2, and PALB2 in breast, colorectal, and…
-
ASCO GU 2025 | Dr. Thomas Powles: EV+P Regimen Redefines Platinum-Based Chemotherapy, Setting a New First-Line Standard for Urothelial Cancer
Urothelial carcinoma (UC) is the second most common malignancy of the urinary system, characterized by poor prognosis and low five-year survival rates. For decades, platinum-based chemotherapy has remained the standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). However, limited clinical benefit and poor tolerability have left many unmet treatment needs.
-
Dr. Neeraj Agarwal: Talazoparib Plus Enzalutamide Extends First-Line OS to Nearly Four Years, Pioneering a New Era in Precision Treatment for mCRPC
The 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) was held from February 13 to 15 in San Francisco, California, bringing together leading experts and researchers in the field of genitourinary oncology. Among the key highlights was the final overall survival (OS) data from the TALAPRO-2 trial, presented by Dr. Neeraj Agarwal from the Huntsman Cancer…
-
ASCO GI 2025 | Dr. Scott Kopetz: EC + FOLFOX Regimen Significantly Improves Response Rates in mCRC, Delivering Rapid and Durable Efficacy
The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25, showcasing the latest advances in gastrointestinal cancer research and treatment strategies. One of the most notable studies was the BREAKWATER trial (Abstract #16), which focused on BRAF V600E-mutant metastatic colorectal cancer (mCRC). This study demonstrated a significant improvement in response rates…
-
New Non-Invasive Screening Strategies Improve MASH Clinical Trials by Reducing Screening Failure Rates
Recently, a collaborative study conducted by researchers from France, Belgium, and China evaluated and compared eight different non-invasive screening tests (NITs) to develop an optimized screening strategy for assessing MASH-related…
Connecting Medical Expertise through Media